Intellia Therapeutics
NTLA
$15.44
-8.31%
Intellia Therapeutics is a gene-editing company focused on developing CRISPR/Cas9-based therapeutics for genetically defined diseases, including ATTR amyloidosis, hereditary angioedema, and sickle cell disease. As a pioneer in in vivo CRISPR therapies, it holds a distinct competitive position with collaborations including Regeneron and Novartis. The current investor narrative centers on the successful Phase 3 trial for its lead CRISPR treatment, which has validated the platform and driven a significant re-rating, though the stock remains a high-risk biotech play dependent on pipeline execution.…
NTLA
Intellia Therapeutics
$15.44
Related headlines
Investment Opinion: Should I buy NTLA Today?
Rating: Buy. The thesis is that Intellia's validated CRISPR platform and upcoming commercial launch justify the premium valuation, with significant upside if revenue materializes. Analyst consensus is bullish, with one source expecting the stock to nearly double from current levels. Supporting evidence: (1) The PS ratio of 14.4x is high but could compress as revenue grows; (2) Revenue estimates average $2.72 billion, implying massive growth; (3) The stock has strong momentum with a 90.7% YTD gain and relative strength of 81.6% over 6 months; (4) The balance sheet is strong with a current ratio of 5.08 and low debt. Risks: The biggest risks are clinical/commercial failure, valuation compression, and cash burn. This Buy rating would downgrade to Hold if the stock approaches the 52-week high of $28.25 without new catalysts, or to Sell if revenue guidance disappoints. Overall, NTLA is fairly valued relative to its potential but overvalued on current fundamentals; it is a speculative buy for risk-tolerant investors.
Sign up to view all
NTLA 12-Month Price Forecast
The AI assessment is bullish with medium confidence. The Phase 3 trial success is a transformative catalyst that validates Intellia's CRISPR platform and positions it for commercial launch. The stock's 90.7% YTD gain reflects this optimism, but the valuation at 14.4x PS is stretched for a pre-revenue company. Key factors supporting the bullish stance include strong momentum, a solid balance sheet, and the potential for a multi-billion-dollar revenue opportunity. However, the high beta of 1.77 and wide analyst estimate ranges introduce significant uncertainty. The stance would upgrade to high confidence if regulatory filing is accepted, and downgrade to neutral if the stock fails to hold above $15 support.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Intellia Therapeutics's 12-month outlook, with a consensus price target around $20.07 and implied upside of +30.0% versus the current price.
Average Target
$20.07
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$12 - $20
Analyst target range
Only 6 analysts cover NTLA, indicating limited institutional interest typical for a small-cap biotech. Consensus estimates show an average EPS estimate of $8.97, but with a wide range from -$2.20 to $79.27, reflecting extreme uncertainty. The average revenue estimate is $2.72 billion, with a low of $115 million and a high of $19.1 billion, suggesting divergent views on the commercial potential of the pipeline. The implied upside/downside cannot be calculated without a target price, but the wide range signals high uncertainty. The limited coverage means the stock may be less efficiently priced and more volatile. Recent news highlights a Wall Street re-rating following Phase 3 data, with one source expecting the stock to nearly double from current levels. However, the lack of formal analyst ratings (buy/hold/sell) and target prices in the data prevents a detailed consensus analysis. Investors should monitor for upcoming analyst initiations or upgrades as the company approaches commercialization.
Bulls vs Bears: NTLA Investment Factors
Intellia Therapeutics presents a high-risk, high-reward opportunity. The bull case rests on the successful Phase 3 trial validating the CRISPR platform, strong balance sheet, and massive revenue potential from a one-time curative therapy. The bear case highlights the pre-revenue status, negative cash flow, extreme valuation at 14.4x PS, and high volatility with a beta of 1.77. Currently, the bull side has stronger evidence due to the Phase 3 de-risking and Wall Street re-rating, but the stock remains speculative. The single most important tension is whether the lead drug achieves commercial success and revenue materializes as expected; if so, the stock could double, but any setback could lead to a -50% decline toward the 52-week low of $7.95.
Bullish
- Phase 3 Success Validates CRISPR Platform: Intellia's successful Phase 3 trial for its lead CRISPR treatment has de-risked the platform and positioned it for commercialization. This milestone drove a 90.7% YTD stock surge and a Wall Street re-rating, with one analyst expecting the stock to nearly double from current levels.
- Strong Balance Sheet with Low Debt: The company has a current ratio of 5.08, indicating ample liquidity to fund operations, and a debt-to-equity ratio of only 0.14, suggesting minimal leverage. This financial stability reduces bankruptcy risk during the pre-revenue phase.
- Outperformance vs. Market and Peers: NTLA has gained 63.7% over the past year versus SPY's 19.1%, with a 1-year relative strength of 44.6%. The stock is trading at 62% of its 52-week range, suggesting room for further upside if momentum continues.
- High Revenue Growth Potential: Analyst revenue estimates average $2.72 billion, with a high of $19.1 billion, reflecting massive commercial potential if the pipeline succeeds. The current PS ratio of 14.4x, while high, could compress rapidly as sales materialize.
Bearish
- Pre-Revenue with Negative Cash Flow: Intellia has no approved products and generates minimal revenue, with a net margin of -609.9% and negative free cash flow (PCF ratio of -2.79). The company burned cash to fund R&D, and profitability is years away even if the lead drug launches successfully.
- Extreme Valuation Risk at 14.4x PS: The trailing PS ratio of 14.4x is high for a development-stage biotech, typically valued at 5-10x sales. This premium implies high expectations; any clinical or commercial disappointment could trigger a severe multiple contraction.
- High Volatility and Speculative Nature: With a beta of 1.77, NTLA is 77% more volatile than the market. The stock has a maximum drawdown of -71.27%, and the 52-week range of $7.95-$28.25 shows extreme price swings. Short-term momentum could reverse sharply.
- Limited Analyst Coverage and Uncertainty: Only 6 analysts cover NTLA, with EPS estimates ranging from -$2.20 to $79.27 and revenue estimates from $115M to $19.1B. This wide dispersion reflects extreme uncertainty about pipeline outcomes, making the stock difficult to value.
NTLA Technical Analysis
NTLA is in a strong uptrend, with the stock up 63.7% over the past year and currently trading at 62% of its 52-week range ($7.95–$28.25). The price sits at $17.56, well above the 52-week low but still 38% below the high, suggesting room for further upside if momentum continues. The 1-year relative strength of 44.6% versus SPY indicates the stock has outperformed the market significantly. Short-term momentum is accelerating sharply, with a 1-month gain of 33.7% and a 3-month gain of 33.7%, both far outpacing the SPY's 1-month decline of 1.3% and 3-month gain of 13.6%. This divergence from the broader market suggests strong stock-specific catalysts, likely the Phase 3 data, driving a breakout. The 1-month relative strength of 35.0% confirms exceptional near-term outperformance. Key support lies near the 52-week low of $7.95, while resistance is at the 52-week high of $28.25. A breakout above $28.25 would signal a new leg higher, while a breakdown below $7.95 would negate the uptrend. With a beta of 1.77, NTLA is 77% more volatile than the market, amplifying both upside and downside risks.
Beta
1.77
1.77x market volatility
Max Drawdown
-71.3%
Largest decline past year
52-Week Range
$8-$28
Price range past year
Annual Return
+27.3%
Cumulative gain past year
| Period | NTLA Return | S&P 500 |
|---|---|---|
| 1m | +19.8% | +2.0% |
| 3m | +14.5% | +10.6% |
| 6m | +48.7% | +8.3% |
| 1y | +27.3% | +20.4% |
| ytd | +67.6% | +10.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NTLA Fundamental Analysis
Intellia is a pre-revenue biotech with no approved products, so revenue is minimal or zero. The most recent quarterly revenue is not provided, but the company is not yet generating meaningful sales. The focus is on pipeline progress; the successful Phase 3 trial for its lead candidate is a major milestone that could lead to commercialization. Net income is negative, with an EPS of -$0.42, reflecting ongoing R&D spending. Gross margin is 76.5%, but this is likely from collaboration revenue rather than product sales. Operating margin is -651.7%, indicating heavy investment in research. The net margin is -609.9%, typical for a development-stage biotech. The company has a strong balance sheet with a current ratio of 5.08, indicating ample liquidity. Debt-to-equity is low at 0.14, suggesting minimal leverage. However, free cash flow is negative (PCF ratio of -2.79), meaning the company is burning cash to fund operations. ROE is -61.5%, reflecting losses relative to equity. The company will need to achieve commercial success or secure additional financing to sustain operations.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NTLA Overvalued?
Since net income is negative, we use the price-to-sales (PS) ratio as the primary valuation metric. The trailing PS ratio is 14.4x, while EV/Sales is 32.7x, reflecting a premium for a pre-revenue biotech. The forward PE is -9.75x, but this is not meaningful due to negative earnings. The PS ratio of 14.4x is high compared to the biotech industry average, which typically ranges from 5-10x for development-stage companies. This premium is justified by the potential of the CRISPR platform and the recent Phase 3 success, but it also implies high expectations. Historical PS data is not available, but given the stock's 90.7% YTD gain, the valuation has expanded significantly. The PEG ratio of 0.09 is misleading due to negative earnings. Overall, the valuation reflects optimism about future revenue from the pipeline, but carries substantial risk if clinical or commercial outcomes disappoint.
PE
-2.4x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-2.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Intellia is pre-revenue with negative net income (EPS -$0.42) and negative free cash flow (PCF ratio -2.79), meaning it burns cash to fund R&D. The operating margin of -651.7% indicates heavy investment, and while the current ratio of 5.08 provides a cushion, the company will eventually need to generate product revenue or raise capital. The debt-to-equity ratio is low at 0.14, but the reliance on pipeline success makes the financials highly binary. Market & Competitive Risks: The stock trades at a premium PS ratio of 14.4x, well above the typical 5-10x for development-stage biotechs, implying high expectations. With a beta of 1.77, NTLA is highly sensitive to market downturns and sector rotation. Competition in gene editing from CRISPR Therapeutics and Editas could erode market share, and regulatory hurdles for a novel therapy remain. The recent Phase 3 success has been priced in, leaving little room for error. Worst-Case Scenario: If the lead drug fails to gain regulatory approval or commercial adoption disappoints, the stock could collapse to its 52-week low of $7.95, representing a -55% decline from the current price of $17.56. Historical max drawdown of -71.27% suggests even deeper losses are possible in a severe downturn, with the stock potentially falling to $5.00 or lower.
FAQ
The key risks are: (1) Clinical/regulatory risk – any setback in the lead drug's approval could cause a -55% decline to the 52-week low of $7.95; (2) Valuation risk – the PS ratio of 14.4x leaves little room for error; (3) Cash burn risk – negative free cash flow (PCF ratio -2.79) may require dilutive financing; (4) Competition risk – other gene-editing companies like CRISPR Therapeutics could erode market share. The most severe risk is commercial failure, which would render the stock nearly worthless.
The 12-month forecast is bullish with a base case target of $18-$24 (45% probability), a bull case of $25-$30 (30% probability), and a bear case of $8-$12 (25% probability). The base case assumes steady pipeline progress without major surprises. The bull case requires regulatory filing and early commercialization success. The bear case involves regulatory setbacks or disappointing uptake. The most likely scenario is the base case, with the stock consolidating near current levels as the market awaits further catalysts.
NTLA is overvalued on traditional metrics, with a trailing PS ratio of 14.4x compared to the biotech industry average of 5-10x for development-stage companies. However, the premium is justified by the validated CRISPR platform and the potential for billions in revenue. The forward PE is negative (-9.75x) due to losses, making PS the only meaningful metric. Relative to its own history, the stock has re-rated significantly following the Phase 3 data. The valuation implies the market expects successful commercialization; if revenue materializes, the stock could be undervalued, but if not, it is significantly overvalued.
NTLA is a high-risk, high-reward biotech stock. The successful Phase 3 trial has de-risked the platform, and Wall Street expects the stock to nearly double from current levels. However, the company is pre-revenue with negative cash flow, and the PS ratio of 14.4x is elevated. For risk-tolerant investors with a long-term horizon, NTLA could be a good buy given the massive revenue potential. Conservative investors should avoid it due to the binary nature of biotech investing. The stock is suitable as a small, speculative allocation within a diversified portfolio.
NTLA is best suited for long-term investment (3-5 years) given its pre-revenue status and dependence on pipeline execution. The stock has a beta of 1.77, making it highly volatile for short-term trading. Short-term traders could capitalize on momentum, but the risk of sharp reversals is high. The company pays no dividend, so total return depends on capital appreciation. A minimum holding period of 3 years is recommended to allow for regulatory approvals and commercial launch. Long-term investors should be prepared for significant drawdowns along the way.